2-Arylethynyl derivatives of (N)-methanocarba adenosine 5′-uronamides are selective A 3 AR (adenosine receptor) agonists. Here we substitute a 1,2,3-triazol-1-yl linker in place of the rigid, linear ethynyl group to eliminate its potential metabolic liability. Docking of nucleosides containing possible short linker moieties at the adenine C2 position using a hybrid molecular model of the A 3 AR (based on the A 2A AR agonistbound structure) correctly predicted that a triazole would maintain the A 3 AR selectivity, due to its ability to fit a narrow cleft in the receptor. The analogues with various N 6 and C2-aryltriazolyl substitution were synthesized and characterized in binding (K i at hA 3 AR 0.3 -12 nM) and in vivo to demonstrate efficacy in controlling chronic neuropathic pain (chronic constriction injury). Among N 6 -methyl derivatives, a terminal pyrimidin-2-yl group in 9 (MRS7116) increased duration of action (36% pain protection at 3 h) in vivo. N 6 -Ethyl 5-chlorothien-2-yl analogue 15 (MRS7126) preserved in vivo efficacy (85% protection at 1 h) with short duration. Larger N 6 groups, e.g. 17 (MRS7138, >90%
Introduction
Two nucleoside agonists of the A 3 adenosine receptor (A 3 AR) are currently in clinical trials for the treatment of autoimmune inflammatory diseases (N 6 -(3-iodobenzyl)-5ʹ′-Nmethylcarboxamidoadenosine, IB-MECA), including rheumatoid arthritis and plaque psoriasis, and hepatocellular carcinoma (2-chloro analogue, Cl-IB-MECA). 1, 2 An even broader range of conditions have been shown to be ameliorated by administration of A 3 AR agonists in animal models, including osteoarthritis, neutropenia, and other inflammatory and infective conditions and chronic neuropathic pain. 3, 4 Chronic neuropathic pain can result from injury or diseases such as cancer and diabetes or from pharmaceutical administration, and its treatment represents an unmet medical need. Thus, the design, synthesis and pharmacological characterization of novel drug-like A 3 AR agonists of high affinity, selectivity and in vivo efficacy are well justified.
The selective A 3 AR agonists that have advanced to clinical trials are adenine-9-riboside derivatives. 1, 2 As an extension of the structure activity relationship (SAR) of AR agonists, we have introduced nucleoside derivatives containing in place of ribose a bicyclo[3.1.0]hexane (methanocarba) ring system, which display increased affinity and/or selectivity for the A 3 AR compared to other AR subtypes. 5 The rigid ribose ring substitute maintains a receptor-preferred conformation and thus decreases an entropic energy barrier for receptor binding. Prototypical nucleosides containing a methanocarba ring system in a North (N) envelope conformation are typically >100-fold more potent at the A 3 AR than the corresponding isomers in the South (S) conformation. 6 A combination of A 3 AR-favoring modifications provided MRS5698 1 and MRS5980 2 (Chart 1A) as highly potent agonists with favorable protective properties in the sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in mice. [7] [8] [9] These rigidified nucleosides contain a C2-arylethynyl group, 10 which is thought to be responsible for the high A 3 AR selectivity, based on the greater structural plasticity of the A 3 AR compared to the A 2A AR, which is more constrained by disulfide bridges in the extracellular loops (ELs). In particular, we have proposed an outward movement of transmembrane helix 2 (TM2) in the A 3 AR in order to accommodate the C2-arylethynyl group and still to maintain conserved H-bonding interactions of the hydroxyls of the ribose-like moiety with the N 6 and N7 of the adenine moiety. 7, 11 However, the presence of an arylethynyl group might be an indication of potential liver toxicity due to its electrophilicity and possible reactivity with glutathione. 12 Therefore, we explored alternative structures that would still maintain the proper geometry of the distal aryl group with respect to the adenosine core structure. A number of alternative C2 substituents were considered and compared by docking to an A 3 AR model: benzyl 3b, phenylethyl 3c, phenylcyclopropyl 3d, phenyl-trans-ethenyl 3e, and phenyl-triazolyl 3f
(Chart 1A, Ar = C 6 H 5 ). A 1,2,3-triazol-1-yl group was predicted to best maintain a similar geometry compared to the potent and selective C2-arylethynyl derivatives.
This work has multiple goals: 1) to identify a general class of compounds that are highly selective agonists of the A 3 AR but do not contain an arylethynyl group, based initially on a comparison of hypothetical structures using molecular modeling; 2) to determine the in vivo efficacy and duration of action in a mouse model of neuropathic pain in order to select preferred candidates for further development.
Results and discussion
We used molecular modeling to predict the effect of logical C2 modifications 3b-f (R = CH 3 , Ar = C 6 H 5 ) on human (h) A 3 AR recognition. Because the rigid, elongated C2 substituent of the series of general formula 3a is key to the >3000-fold A 3 AR selectivity vs. the A 2A AR, a substitution for the ethynyl group would need to maintain a similar extended conformation when bound to the receptor. The receptor model used for docking was our recently published hybrid homology model of the A 3 AR. 7, 11 The agonist-bound hA 2A AR X-ray structure 13 was used as a template for all of the TMs, except for the upper part of TM2. 11 Figure 1 compares the effects of these substitutions when the nucleosides are docked in the hybrid model, and Table 1 summarizes the features of the different proposed linkers (substitutes for C≡C of 3a). Docking simulations showed that all the derivatives bearing the proposed alternative C2 substituents were able to fit the binding site of the A 3 AR hybrid model in an orientation analogous to the one observed for the original arylethynyl derivatives. Such a binding pose has been well validated in previous studies 7, 11 and shows all the interactions key for agonist binding at ARs. 13 In particular, the pseudo-sugar moiety forms H-bonds with Thr94 (3.36), Ser271 (7.42) and His272 (7.43) (numbers in parenthesis follow the Ballesteros-Weinstein numbering system), 14 the adenine core forms two H-bonds with Asn250 (6.55) and a π-π stacking with Phe168 (EL2), the N 6 substituent interacts with hydrophobic residues on EL2 such as Val169 and the C2 group is directed towards TM2 ( Figure 1A ).
Thus, to select the best linker to be used in the new series of derivatives, we analyzed the various alternatives in a detailed manner. The rigid, elongated C2 substituent is a key feature for high A 3 AR selectivity, because of the greater structural plasticity of the A 3 AR compared to the A 2A AR as previously proposed, 7 therefore we predicted higher selectivity at the A 3 AR for those derivatives bearing rigid and elongated linkers, such as 3d-f. These substitutions might approximate the docked position of the terminal aryl group of known selective agonist series 3a ( Figure 1A ).
The terminal phenyl ring need not be coplanar with the adenine ring, but a substantial bending within the C2 substituent would not be favored. Compounds 3b and 3c, even though predicted to bind the A 3 AR, would probably interact also with the A 2A AR because of flexibility in the position of the terminal phenyl ring, possibly resulting in reduced selectivity. Moreover, the C2 linker is accommodated in a narrow region between Phe168 (EL2) and Ile268 (7.39) (~4 Å, Figure 1B ). Therefore, we predicted a higher affinity at the A 3 AR for those derivatives bearing a planar linker, such as 3a, 3e and 3f, compared to those with wider and out-of-plane linkers, such as 3b-d. In light of these considerations, compounds 3e and 3f would be the best alternatives to preserve the high affinity and selectivity of the arylethynyl group. However, because of the potential chemical and photochemical reactivity of a styryl group, we decided not to synthesize derivatives of compound 3e but to focus on triazolyl derivatives. In fact, as highlighted in Table 1 , triazole series 3f seemed to be the best alternative to alkynyl series 3a, because of its stability, its rigid, planar and elongated C2 group ( Figure S1 , Supporting information) and its synthetic feasibility. The terminal phenyl rings of 3a and 3f are largely overlapping when docked to the A 3 AR. However, 3f is slightly more elongated than 3a
(by 0.8 Å), and it was shown previously that rigid C2 substituents more extended than phenylethynyl are tolerated at the A 3 AR.
7
Nucleoside derivatives 5 -20 (Table 2) cycloaddition of a congeneric set of 2-azidoadenosines (30 -34) and arylacetylenes, 16 which link adenine and C2-terminal aryl moieties (Scheme 1). The azide group is introduced on adenine via reaction of sodium azide with the corresponding 2-iodo intermediates (25 -29), which were prepared as described from L-ribose. 17 The product 2-(1,2,3-triazol-1-yl) nucleosides that were subsequently tested in binding assays were demonstrated using HPLC to be of high purity (>95%). Click chemistry of (N)-methanocarba adenosines was used previously to prepare various high affinity A 3 AR ligands. 18 Radioligand binding assays were performed at three subtypes of hARs that are relevant for this chemical series and at the mouse (m) A 3 AR, which were stably expressed in mammalian cells, as previously reported ( After confirming the A 3 AR-selectivity, the A 3 AR agonists were screened in vivo in the mouse CCI model. 21 The protection by A 3 AR agonists against chronic neuropathic pain occurs at both central and peripheral sites of action. 11 The methods used were as reported, 7, 8 and the agonist was given by oral gavage (3 µmol/kg) on day 7 after sciatic nerve ligation, i.e. the time when peak pain develops. The paw withdrawal threshold (PWT) was measured up to 5 h after drug administration. The maximal efficacy in vivo and the duration of action were indicated (Table 3 ). Each compound reached its peak protection against chronic neuropathic pain by 1 h after administration. In the earlier alkynyl series 8 peak protection was achieved between 0.5 and 2 h after administration and maintained up to 3 h (as with 5-chlorothienyl derivative 2, which suppressed neuropathic pain to the degree of 83% protection at 3 h). By comparison, compound 1 at the same dose displayed only 24% protection after 3 h. 8 Here, at 1 h after drug treatment the mechanoallodynia was a nearly completely reversed by some triazole derivatives, i.e.
pyrimidin-2-yl 9, N-methylpyrazolyl 11, 5-chlorothien-2-yl 15 and 5-bromothien-2-yl 19
analogues and compounds 16 -18. For N 6 -methyl analogues, the majority of the pain protection by the triazolyl derivatives waned by the 3 h time point ( Figures 3A,B) . In analogues containing the same terminal 5-chlorothiophene group found in very efficacious and long-acting agonist 2, an N 6 -ethyl group in 15 compared to the N 6 -methyl homologue 14 produced a higher maximal protection at 1 h, i.e. 85% vs. 67%, respectively. A 2-pyrimidyl group in 9 favored duration of action in vivo, with 36% of the protection remaining at 3 h, which would not have been predicted by its relatively weak mA 3 AR affinity. Larger N 6 groups, e.g. 3-chlorobenzyl in 17 (>90% protection at 1 and 3 h), combined with a terminal chlorothienyl group greatly enhanced in vivo activity ( Figure 3C ). At a lower dose (1 µmol/kg), 17 produced the same duration of protection but the maximal effect reached a plateau at ~70% ( Figure S2 , Supporting Information). Off-target activities of several triazole derivatives (12, 14) were also determined in a broad receptor binding screen (Supporting Information). 22 The only interactions at IC 50 <10 µM were with H 2 histamine (12, 50% inhibition at 10 µM) and sigma2 receptors (12, 50%; 14, 62%) and the peripheral benzodiazepine receptor (TSPO, 14, 54%). These few interactions reinforced the A 3 AR selectivity of these representative compounds.
Conclusions
Derivatives of selective A 3 AR agonists containing a triazole linker in place of an ethynyl group, a preferred substitution as predicted using molecular modeling, were prepared and shown to parallel the ethynyl series in receptor affinity and selectivity. Docking of possible linker moieties at the C2 position, using a molecular model of the A 3 AR, correctly predicted that the receptor affinity and selectivity would be maintained due to common structural features that favored selective binding at the A 3 AR. A planar C2-triazole linker fit well in a narrow cleft when docked in the receptor binding site. The effects of N 6 substitution were also probed. All of these analogues contain a (N)-methanocarba ring system to optimize A 3 AR affinity, which improves the selectivity in comparison to the ribose series. 5 The analogues were characterized in binding and in vivo assays to demonstrate efficacy in controlling chronic neuropathic pain in agreement with A 3 AR selectivity. An N 6 -ethyl group in 15 preserved in vivo activity compared to N 6 -methyl and binding selectivity, while larger groups reduced A 3 AR selectivity. In comparison to the activities of the corresponding 2-arylethynyl derivatives, the duration of action of many analogues tended to be shorter. 8 Nevertheless, among N 6 -methyl derivatives a terminal pyrimidin-2-yl group in 9 extended the duration of action compared to other aryl groups. A highly prolonged and full efficacy in reversing mechanoallodynia was achieved in a few derivatives, i.e. 16 -18 that contained larger N 6 substitution. The most enhanced in vivo efficacy and duration was seen with N 6 -(3-chlorobenzyl derivative 17 (nearly full protection up to 4 h).
The use of X-ray structures of closely related GPCRs in homology modeling, docking and screening has facilitated understanding ligand recognition and drug discovery for the A 3 AR and for other receptors. 23 Here, the effects of potential structural changes were Table 2 . e n = 1.
ND -not determined.
